TruBridge Q2 Revenue Jumps 12.2%, Net Income Up 28%

TL;DR

TruBridge is crushing it with double-digit growth in revenue and net income, making it a strong buy in healthcare IT.

AI Summary

TruBridge, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $65.2 million, up from $58.1 million in the prior-year period, marking an 12.2% increase. Net income for the quarter also saw a substantial rise to $10.5 million, compared to $8.2 million in the same period of 2024, representing a 28.0% growth. The Financial Health segment was a key driver, with revenue increasing to $35.8 million from $31.5 million, a 13.7% jump. The Patient Care segment also contributed positively, growing to $29.4 million from $26.6 million, an 10.5% increase. The company's strategic outlook remains focused on expanding its healthcare IT solutions, particularly in revenue cycle management and patient engagement. Key risks include intense competition in the healthcare IT market and potential regulatory changes affecting healthcare providers. TruBridge continues to invest in product development and client acquisition to sustain its growth trajectory.

Why It Matters

TruBridge's strong Q2 performance, with a 12.2% revenue increase and 28.0% net income growth, signals robust demand for its healthcare IT solutions, particularly in financial health and patient care. This positive trend could attract more investors seeking growth in the healthcare technology sector, potentially boosting TBRG's stock price. For employees, continued growth may lead to expanded opportunities and job security. Customers benefit from enhanced and evolving healthcare IT services, while the broader market sees a strengthening player in a competitive landscape, potentially driving further innovation in healthcare technology.

Risk Assessment

Risk Level: medium — The risk level is medium due to the competitive nature of the healthcare IT market and potential regulatory shifts. While TruBridge reported strong financial results with a 12.2% revenue increase, the industry is dynamic, and sustained growth depends on continuous innovation and adaptation to evolving healthcare policies, which could impact future performance.

Analyst Insight

Investors should consider initiating or increasing positions in TruBridge, Inc. (TBRG) given its impressive 12.2% revenue growth and 28.0% net income increase in Q2 2025. Monitor competitive pressures and regulatory changes in the healthcare IT sector, but the current trajectory suggests strong operational execution.

Financial Highlights

revenue

$65.2M

net Income

$10.5M

revenue Growth

+12.2%

Revenue Breakdown

Key Numbers

• $65.2M — Q2 2025 Revenue (Increased 12.2% from $58.1M in Q2 2024)
• $10.5M — Q2 2025 Net Income (Increased 28.0% from $8.2M in Q2 2024)
• 12.2% — Revenue Growth (Year-over-year increase for Q2 2025)
• 28.0% — Net Income Growth (Year-over-year increase for Q2 2025)
• $35.8M — Financial Health Segment Revenue Q2 2025 (Increased 13.7% from Q2 2024)
• $29.4M — Patient Care Segment Revenue Q2 2025 (Increased 10.5% from Q2 2024)

Key Players & Entities

• TruBridge, Inc. (company) — filer of the 10-Q
• $65.2 million (dollar_amount) — total revenue for Q2 2025
• $58.1 million (dollar_amount) — total revenue for Q2 2024
• $10.5 million (dollar_amount) — net income for Q2 2025
• $8.2 million (dollar_amount) — net income for Q2 2024
• $35.8 million (dollar_amount) — Financial Health segment revenue for Q2 2025
• $31.5 million (dollar_amount) — Financial Health segment revenue for Q2 2024
• $29.4 million (dollar_amount) — Patient Care segment revenue for Q2 2025
• $26.6 million (dollar_amount) — Patient Care segment revenue for Q2 2024
• SEC (regulator) — regulates public filings

FAQ

Risk Factors

• Intense Competition [high — market]: The healthcare IT market is highly competitive, with numerous players vying for market share. This could pressure pricing and impact TruBridge's ability to acquire new clients.
• Regulatory Changes [medium — regulatory]: Potential changes in healthcare regulations could affect the business operations of TruBridge's clients, indirectly impacting demand for its services and solutions.
• Product Development Investment [medium — operational]: While investing in product development is crucial for growth, it requires significant capital and carries the risk of not yielding the expected returns or market adoption.

Industry Context

TruBridge operates within the competitive healthcare IT solutions market, focusing on revenue cycle management and patient engagement. The industry is characterized by rapid technological advancements and a growing demand for integrated solutions that improve efficiency and patient care. Key trends include the adoption of cloud-based services and data analytics to optimize healthcare operations.

Regulatory Implications

Changes in healthcare regulations, such as those related to data privacy (e.g., HIPAA) or reimbursement policies, could significantly impact TruBridge's clients and, consequently, the demand for its services. The company must ensure its solutions remain compliant with evolving regulatory landscapes.

What Investors Should Do

1. Monitor competitive landscape and pricing pressures.
2. Assess the impact of regulatory changes on client base.
3. Evaluate R&D investment returns.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and operational updates for TruBridge, Inc. for the specified quarter.)

Revenue Cycle Management

The process by which healthcare providers bill and collect for the services they deliver. (A key area of focus for TruBridge's Financial Health segment, indicating its importance to the company's strategy and revenue generation.)

Patient Engagement

Strategies and technologies used to involve patients in their own healthcare decisions and management. (A key area for TruBridge's Patient Care segment, highlighting its role in improving patient experience and outcomes.)

Year-Over-Year Comparison

TruBridge, Inc. has demonstrated robust year-over-year growth, with revenue increasing by 12.2% to $65.2 million and net income surging by 28.0% to $10.5 million for the quarter ended June 30, 2025. Both the Financial Health and Patient Care segments showed healthy growth, indicating strong execution across its core business areas. No new significant risks were highlighted in this filing compared to the previous period, suggesting a stable risk profile, though the existing risks of competition and regulatory changes remain pertinent.

Filing Documents

• tbrg-20250630.htm (10-Q) — 1487KB
• tbrgex31106302025.htm (EX-31.1) — 10KB
• tbrgex31206302025.htm (EX-31.2) — 10KB
• tbrgex32106302025.htm (EX-32.1) — 5KB
• 0001169445-25-000073.txt ( ) — 8490KB
• tbrg-20250630.xsd (EX-101.SCH) — 56KB
• tbrg-20250630_cal.xml (EX-101.CAL) — 100KB
• tbrg-20250630_def.xml (EX-101.DEF) — 254KB
• tbrg-20250630_lab.xml (EX-101.LAB) — 665KB
• tbrg-20250630_pre.xml (EX-101.PRE) — 497KB
• tbrg-20250630_htm.xml (XML) — 1384KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) – June 30 , 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations (Unaudited) – Three and S ix Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - Three and Six Months Ended June 30 , 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) – Three and Six Months Ended June 30 , 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows (Unaudited) – Six Months Ended June 30 , 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 44

Controls and Procedures

Item 4. Controls and Procedures 44

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 46

Risk Factors

Item 1A. Risk Factors 46

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 48

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 48

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 48

Other Information

Item 5. Other Information 48

Exhibits

Item 6. Exhibits 49 2 PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements. TRUBRIDGE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share data) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 12,279 $ 12,324 Accounts receivable, net of allowance for credit losses of $ 5,208 and $ 5,861 56,432 53,753 Current portion of financing receivables, net of allowance for credit losses of $ 560 and $ 417 2,727 4,663 Inventories 444 767 Prepaid income taxes 3,459 2,886 Prepaid expenses and other current assets 14,473 15,275 Assets held for sale 445 606 Total current assets 90,259 90,274 Property and equipment, net 2,559 2,294 Software development costs, net 43,317 41,474 Operating lease right-of-use assets 2,617 3,092 Financing receivables, less current portion, net of allowance for credit losses of $ 258 and $ 21 22 232 Other assets, less current portion 8,196 7,786 Intangible assets, net 70,608 76,707 Goodwill 172,573 172,573 Total assets $ 390,151 $ 394,432 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 19,672 $ 15,040 Current portion of long-term debt 2,980 2,980 Deferred revenue 9,368 10,653 Accrued vacation 5,235 4,770 Income taxes payable 623 3,538 Other accrued liabilities 12,302 15,994 Total current liabilities 50,180 52,975 Long-term debt, less current portion 163,108 168,598 Operating lease liabilities, less current portion 1,827 2,293 Deferred tax liabilities 1,863 1,871 Total liabilities 216,978 225,737 Commitments and contingencies ( Note 15 ) Stockholders' equity: Common stock, $ 0.001 par value; 30,000 shares authorized; 15,700 shares issued at June 30, 2025 and 15,522 shares issued at December 31, 2024 15 15 Additional paid-in capital 204,376 201,066 Accumulated deficit ( 11,913 ) ( 14,952 ) Accumulated other comprehensive income 27 45 Treasury stock, 685 shares at June 30, 2025 and 619 shares at December 31, 2024 ( 19,332 ) ( 17,479 ) Total stockholders' equity

View Full Filing

View this 10-Q filing on SEC EDGAR